ClinicalTrials.gg
RecruitingNCT06708156Updated Dec 24, 2024

The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression

A Phase 3 interventional study of Atropine sulfate eye drops 0.01% and Atropine sulfate eye drops 0.02% in Myopia and Myopia Progression, sponsored by Oupushifang Pharmaceutical Technology Co., Ltd.. Recruiting at 25 sites in China. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2024-12-24.

Sponsored by Oupushifang Pharmaceutical Technology Co., Ltd. · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jun 2024, registered Nov 2024).
  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
606
Allocation
Randomized
Ages
6 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies testing atropine in Myopia — 17 open to participants now, 24 under way, 9 of them phase 3. Atropine · Myopia.

Planned enrollment
4th of 54
606 · median 144
Started
2024
with 4 others
Phase 3
13 of 54
5 open now
Primary completion
2026-12
later than 9 of 23 live
Registered
40th of 54
by date

Among the 54 studies testing atropine in Myopia, this one is the 4th largest by planned enrollment, is one of 5 that started in 2024, is one of 13 in phase 3, reaches primary completion later than 9 of the 23 other live ones, and was the 40th registered.

Myopia

1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

17 of the 54 studies testing atropine in Myopia are open now, in 11 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About atropine

Atropine: first FDA approval 1960 (LOMOTIL), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.

This study: 6 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing atropine in Myopia, or all of them as a file.
02

Study summary

The clinical trial aims to test the effectiveness and safety of two low-dose atropine sulfate eye drops for delaying myopia progression in children and adolescents.

Primary Objective: evaluate the effectiveness of 0.01% and 0.02% atropine sulfate eye drops for 96 weeks compared to placebo in delaying myopia progression in children and adolescents. Secondary Objective: evaluate the safety of two low-concentration atropine sulfate eye drops (0.01%/0.02%) in delaying myopia progression in children and adolescents.

Exploratory Objective:

  1. the efficacy and safety of two low-concentration atropine sulfate eye drops (0.01%/0.02%) for 144 weeks.
  2. evaluate the rebound effect of two low-concentration atropine sulfate eye drops (0.01%/0.02%) after discontinuation.
03

Conditions studied

  • Myopia
  • Myopia Progression

Browse trials for

Keywords

  • Myopia
  • Atropine
04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The legal guardian of the subject voluntarily signed the written , and the subject over 8 years is required to sign the written informed consent voluntarily.
  2. Patients with myopia aged 6 to 12 years, including cut-offs.
  3. The equivalent spherical refraction ranges from -1.00 D to -4.00 D (automatic optometry under a cycloplegia condition) in both myopia eyes at inclusion screening.
  4. The astigmatism of both eyes was ≤ 1.50 D under a cycloplegia condition at inclusion screening.
  5. The antimetropia (measured by equivalent spherical refraction) is \< 2.00 D at inclusion screening.
  6. Able to comply with study requirements, attend all study visits (including telephone visits), and be willing to receive random grouping of atropine treatment or placebo.

Exclusion criteria

Exclusion Criteria:

  1. Allergic to this product or its .
  2. Suffering from eye diseases that may affect vision (e.g. lens diseases such as cataracts, glaucoma, fundus macular disease, keratopathy, uveitis, retinal detachment, severe vitreous opacity, etc., manifest strabismus, nystagmus, ocular acute inflammatory disease), history of recurrent chronic ocular inflammation, or any other ocular pathology (e.g., angular stenosis, shallow anterior chamber).
  3. Intraocular pressure of either eye is > 21 mmHg or \<10 mmHg at screening.
  4. Use of low-concentration (0.05% and below) atropine sulfate eye drops (including various in-hospital preparations, except for test drugs) and orthokeratology lenses (OK lenses) within 6 months before the screening.
  5. Use of other myopia control methods such as instruments (multifocal glasses, progressive multifocal glasses, etc.), medications (the use of cycloplegic agents for examinations such as optometry is allowed), and others (including traditional Chinese medicine, auricular acupuncture, massage, accommodative flippers, red light therapy instrument, etc.) within 3 months before screening.
  6. Those who have participated in other clinical trials and received drug or medical device interventions within 3 months before screening.
  7. Systemic or topical use of drugs that affect the efficacy evaluation, such as anticholinergics: atropine, pirenzepine, etc., and cholinomimetics: pilocarpine, etc. within 1 week before screening.
  8. Combined with severe immune system disease, central nervous system disease, Down syndrome, asthma, cardiopulmonary insufficiency, liver and kidney dysfunction, etc.
  9. Surgical intervention (ocular or systemic) within 6 months before screening, or planned surgery during the study.
  10. Heart rate sustained (more than 10 minutes) greater than 120 beats/min at screening (after 10 minutes of rest if the shows a heart rate greater than 120 beats per minute, the ECG should be retested 10 minutes later. If the retest result below 120 beats/min, the screening is successful; If the retest result is still >120 beats/min, screening failed).
  11. Need for ocular use or systemic oral during the study. Intranasal, inhaled, topical cutaneous, intra-articular, perianal steroids, and short-term oral steroids (i.e., continuous use for \< 2 weeks).
  12. Other conditions that are considered unsuitable by the investigator.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
606 participants (estimated)

Study arms

  • Active comparator
    Experimental group (0.01% atropine sulfate eye drops)

    1 drop in each eye, once a day, every night before sleep, gently press the dacryocyst on both sides for about 1 minute.

    Drug: Atropine sulfate eye drops 0.01%

  • Active comparator
    Experimental group (0.02% atropine sulfate eye drops)

    1 drop in each eye, once a day, every night before sleep, gently press the dacryocyst on both sides for about 1 minute.

    Drug: Atropine sulfate eye drops 0.02%

  • Placebo comparator
    Control group (placebo eye drops)

    1 drop in each eye, once a day, every night before sleep, gently press the dacryocyst on both sides for about 1 minute.

    Drug: Placebo eye drops

Interventions

  • DrugAtropineStudies of AtropineAtropine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Drug: 0.01% atropine sulfate eye drops Dosage form and strength: 0.01% (0.4 mL: 0.04 mg) eye drops Usage: both eyes, 1 drop in each eye, once a day, every night before sleep, gently press the dacryocyst on both sides for about 1 minute.

  • DrugAtropineStudies of AtropineAtropine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Drug: 0.02% atropine sulfate eye drops Dosage form and strength: 0.02% (0.4 mL: 0.08 mg) eye drops Usage: both eyes, 1 drop in each eye, once a day, every night before sleep, gently press the dacryocyst on both sides for about 1 minute.

  • DrugPlacebo eye drops

    Drug: placebo eye drops Dosage form and strength: 0.4 mL eye drops Usage: both eyes, 1 drop in each eye, once a day, every night before sleep, gently press the dacryocyst on both sides for about 1 minute.

06

What researchers measure

Primary outcomes

  1. Effective change from baseline in equivalent spherical refraction at Week 96 visit

    The inter-group difference in the value of change from baseline in equivalent spherical refraction after 0.01% or 0.02% atropine sulfate eye drops versus placebo under a cycloplegia condition at the Week 96 visit

    Time frame: At the Week 96 visit

Secondary outcomes

  1. Effective change from baseline in eye axis length at 24 months

    Value of change from baseline in eye axis length at 24 months of dosing (0.02% atropine vs. placebo; 0.01% atropine vs. placebo)

    Time frame: At the Week 96 visit

  2. Effective change from baseline in refraction at 12 months

    Change from baseline in refraction (automatic optometric equivalent spherical refraction under a cycloplegia condition) at 12 months (0.02% atropine vs. placebo; 0.01% atropine vs. placebo)

    Time frame: At the Week 48 visit

  3. Effective change from baseline in ocular axis length at 12 months

    Change from baseline in ocular axis length at 12 months of dosing (0.02% atropine vs. placebo; 0.01% atropine vs. placebo)

    Time frame: At the Week 48 visit

  4. Progression of refraction ≤0.50 D at 12 months and 24 months and percentage

    Progression of refraction (automatic optometric equivalent spherical refraction under a cycloplegia condition) ≤0.50 D at 12 months and 24 months (0.02% atropine vs. placebo; 0.01% atropine vs. placebo) and percentage (0.02% atropine vs. placebo; 0.01% atropine vs. placebo)

    Time frame: At the Week 48 and Week 96 visits

  5. Progression of refraction ≤0.75D at 12 months and 24 months and percentage

    Progression of refraction (automatic optometric equivalent spherical refraction under a cycloplegia condition) ≤0.75D at 12 months and 24 months and percentage (0.02% atropine vs placebo; 0.01% atropine vs placebo)

    Time frame: At the Week 48 and Week 96 visits

  6. Progression of refraction ≤1.00D at 12 months and 24 months and percentage

    Progression of refraction (automatic optometric equivalent spherical refraction under a cycloplegia condition) ≤1.00D at 12 months and 24 months (0.02% atropine vs. placebo; 0.01% atropine vs. placebo) and percentage (0.02% atropine vs. placebo; 0.01% atropine vs. placebo)

    Time frame: At the Week 48 and Week 96 visits

  7. Progression of refraction >1.00D at 12 months and 24 months and percentage

    Progression of refraction (automatic optometric equivalent spherical refraction under a cycloplegia condition) \>1.00D at 12 months and 24 months of dosing and percentage (0.02% atropine vs. placebo; 0.01% atropine vs. placebo)

    Time frame: At the Week 48 and Week 96 visits

  8. Percentage of patients with 30% and 50% reduction in myopia progression at 12 and 24 months

    Percentage of patients with 30% and 50% reduction in myopia progression at 12 and 24 months of medication compared to control (0.02% atropine versus placebo; 0.01% atropine versus placebo)

    Time frame: At the Week 48 and Week 96 visits

  9. Change from baseline in other ocular morphologic measures at 12 months and 24 months

    Change from baseline in other ocular morphologic measures (e.g., corneal curvature, vitreous chamber depth, choroidal thickness) at 12 months and 24 months of dosing (0.02% atropine vs. placebo; 0.01% atropine vs. placebo)

    Time frame: At the Week 48 and Week 96 visits

07

Study locations

25 of 25 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Dec 2026, 30 months after the start.

Of 25 phase 3 interventional studies under Myopia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 57. This study's planned 30 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2024
First posted
Nov 27, 2024
StartActual
Jun 15, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Dec 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06708156
Lead sponsor
Oupushifang Pharmaceutical Technology Co., Ltd.
Collaborators
Seefunge Pharmaceutical Technology Co., Ltd., AUTEK China Inc.
Responsible party
Sponsor
First posted
Nov 27, 2024
Start date
Jun 15, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Dec 24, 2024

Study contacts

Liang Gao
Contact
9071044822@qq.com
0086-15056564539
Shaolong XUE, Dr.
Contact
xuesl@seefunge.com
0086-18565027687
Ningli Wang, Postdoctoral
principal investigator · Beijing Tongren Hospital Affiliated to Capital Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atropine

Start the discussion